Clinical trial
A Phase 2, Randomized, Placebo-controlled, Double-blind Study of TAS-303 in Female Patients With Stress Urinary Incontinence
NCT04512053 is registered in ClinicalTrials.gov with Taiho Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Placebo-controlled, Double-blind Study of TAS-303 in Female Patients With Stress Urinary Incontinence
- Lead sponsor
- Taiho Pharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 4, 2020
- Completion date
- December 22, 2021
- Enrollment
- 231 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
stress urinary incontinence